| Proposed Ticker: INGN | 301 Congress Avenue, Suite 1850 | |
| Exchange: NASDAQ-National Market | Austin, Texas 78701 | |
| Industry: Manufacturing | (512) 320-5010 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 9/3/96 | |
| U.S. Shares Filed: | 2,700,000 | Filing Range: | $10.00 - $12.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $29,700,000 | |
| Primary Shares: | 2,700,000 | Expenses: | $750,000 | |
| Secondary Shares: | 0 | Shs Out After: | 10,863,769 | |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Genesis Merchant Group Securities | Co-manager | (800) 833-6482 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/96 | 6/30/96 | ||||
| Revenue: | $10.45 | Assets: | $8.97 | ||
| Net Income: | -$1.33 | Liabilities: | $2.05 | ||
| EPS: | -$0.18 | Equity: | $6.92 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Introgen Therapeutics, Inc. is a leader in the development of gene therapy products to treat cancer by direct introduction of the therapeutic gene inside the body. Gene therapy is a new technology that is being developed using genetic materials as therapeutic agents to treat genetic defects causing cancer and other diseases. For treating cancer, gene therapy seeks to restore or correct missing or aberrant gene functions either by the addition of normal genes or by neutralizing the activity of defective genes. Gene therapy involves two categories of gene cancer therapy products: 1) "gene replacement" products based on the p53 tumor suppressor gene and 2) "gene blocking" products designed to neutralize the activity of a mutant K-ras designed to neutralize the activity of a mutant K-ras oncogene. Missing or dysfunctional p53 tumor suppressor genes are the single most common genetic alteration in cancer discovered to date and occur in over 50% of human cancers. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund product research and development, product clinical trials, manufacturing scale-up and capacity expansion, support of sponsored research programs, marketing and sales organization development, and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.